Drug Trial News

RSS

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer

A new study has shown that AstraZeneca's Lynparza (olaparib) can significantly slow the progress of breast cancer that is caused partially due to mutations of the culprit gene called BRCA. BRCA gene mutations are responsible for around 3% of all breast cancers. These cases of the disease that have a basis in the gene are notoriously difficult to treat and women who are tested positive for this gene may even opt for removal of their breasts before even the cancer strikes. Noted actress Angelina Jolie went for a similar prophylactic mastectomy.

5 Jun 2017

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%.

5 Jun 2017

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer disclosed a 71% pathologic complete response to the combination treatment in the initial phase I trial.

2 Jun 2017

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.

2 Jun 2017

Common acne medication can slow progress of relapsing-remitting MS, trial shows

A Canadian clinical trial led by researchers at the University of Calgary's Hotchkiss Brain Institute, at the Cumming School of Medicine, shows that minocycline, a common acne medication, can slow the progress of relapsing-remitting multiple sclerosis (MS) in people who have recently experienced their first symptoms.

1 Jun 2017

Experimental drug increases progression-free survival in pancreatic cancer patients, clinical trial shows

By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a Phase 2 clinical trial led by an investigator at Fred Hutchinson Cancer Research Center.

1 Jun 2017

Phase 2 clinical study examines Alzheimer's disease drug to treat adults with Down syndrome

A phase 2 clinical trial in young adults with Down syndrome of a drug being investigated for the treatment of Alzheimer's disease supports further investigation of its potential.

1 Jun 2017

Small clinical trial reveals promising results of triple immunotherapy in treating rare skin cancer

Three out of four patients treated with an experimental combination of three different therapies for the rare skin cancer known as Merkel cell carcinoma are in complete remission following the treatment, according to study results from a small clinical trial led at Fred Hutchinson Cancer Research Center.

31 May 2017

Dual therapy effective as second-line treatment for patients infected by HIV with multiple mutations

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa (Cameroon, Burkina Faso, and Senegal), shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations.

29 May 2017

Dragon Master Foundation to fund DIPG trial that will make patient data available live in the cloud

Dragon Master Foundation has announced plans to provide $300,000 in funding for the first clinical trial that will make patient data available live in the cloud while the trial is underway.

27 May 2017

Clinical study tests 100-year-old drug in children with autism spectrum disorder

In a small, randomized Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism.

26 May 2017

Trial shows promising results for new medicine in treating severe asthma patients

A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.

25 May 2017

Study: Angiotensin II can safely improve blood pressure among critically ill patients with hypotension

Sixty years after Cleveland Clinic researchers first isolated the role of angiotensin II in controlling blood pressure, a new international study led by Cleveland Clinic researchers shows that the compound can safely improve blood pressure among critically ill patients who are experiencing life-threatening hypotension, or low blood pressure.

22 May 2017

Rush clinical trial offers new immunotherapy combination to patients fighting kidney cancer

Rush University Medical Center is among the first hospitals in the nation, and the only one in Illinois, to provide patients fighting advanced kidney access to a new combination immunotherapy that targets different immune system cells and processes than a widely used therapy that has been proven effective for some patients but had little effect on others.

22 May 2017

New clinical trial offers hope for patients with hard-to-treat cancer caused by asbestos

Patients with a hard-to-treat type of cancer are being given new hope in a ground-breaking clinical trial. Researchers at the University of Southampton and the University of Leicester are trialing a drug that could boost the body's immune system to fight off mesothelioma, which can be caused by asbestos.

19 May 2017

Phase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patients

ImmusanT, Inc., a clinical-stage company developing Nexvax2, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet in HLA-DQ2.5+ patients with celiac disease, today announced the publication of positive data from two Phase 1 clinical trials of Nexvax2 in celiac disease.

12 May 2017

Drug Trial News

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

Common acne medication can slow progress of relapsing-remitting MS, trial shows

Experimental drug increases progression-free survival in pancreatic cancer patients, clinical trial shows

Phase 2 clinical study examines Alzheimer's disease drug to treat adults with Down syndrome

Small clinical trial reveals promising results of triple immunotherapy in treating rare skin cancer

Dual therapy effective as second-line treatment for patients infected by HIV with multiple mutations

Dragon Master Foundation to fund DIPG trial that will make patient data available live in the cloud

Clinical study tests 100-year-old drug in children with autism spectrum disorder

Trial shows promising results for new medicine in treating severe asthma patients

Study: Angiotensin II can safely improve blood pressure among critically ill patients with hypotension

Rush clinical trial offers new immunotherapy combination to patients fighting kidney cancer

New clinical trial offers hope for patients with hard-to-treat cancer caused by asbestos

Phase 1 clinical studies reveal safety, tolerability of therapeutic vaccine in celiac disease patients

Phase 1 trial shows safety and tolerability of oncolytic HSV-1 for children, young adults with cancer

Boosting clinical trial research in London

New clinical study aims to prevent onset of epilepsy in children with tuberous sclerosis

FDA approves new AML drug after clinical testing at Dana-Farber

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News